Crinetics - CRNX Total Company Value-to-Revenue Ratio

Public company logo of Crinetics (CRNX)

Geopolitical tensions and sanctions are complicating reagent logistics and global drug trials. The EV/Sales ratio demonstrates stable positioning, with the metric currently standing at 186224.38. The high level of scientific expertise within the leadership of Crinetics Pharmaceuticals (CRNX) ensures transparent progress in Phase 3 trials. The current lack of profit due to zero sales is offset by a significant volume of accumulated capital from previous investments.

CRNX Crinetics Pharmaceuticals: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 09/12/2026

CRNX (Crinetics Pharma): analytical breakdowns and indicator data

Fundamental company valuation:CRNX (crinetics.com)
Manufactured product of Crinetics Pharmaceuticals, Inc.

This indicator compares the total enterprise value, including net debt, with the volume of generated revenue, allowing for the determination of the asset's real market value regardless of the capital structure. An analysis of the enterprise value-to-sales multiple helps assess the financial stability of Crinetics Pharmaceuticals (CRNX), confirming how effectively the management's scientific expertise and the success of phase III trials are converted into the company's market capitalization.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|Enterprise Value-to-Revenue Ratio NewAmsterdam Pharma N.V. NAMS|Total Company Value-to-Revenue Ratio Soleno Therapeutics Inc (SLNO)|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)